Montreal, March 26, 2024 – Developments in gene therapy for hemophilia B have come fast and furious over the last several months. In October 2023,...
To access charts informing you of products in the PIPELINE, please CLICK HERE. To access charts informing you of CURRENT coagulation products, please CLICK HERE.
CLICK HERE to access the periodic review of novel treatments in hemophilia and other bleeding disorders by the European Haemophilia Consortium.
Hamilton, January 22, 2024 – McMaster University, in collaboration with CSL Behring, has announced a new gene therapy trial for etranacogene dezaparvovec (Hemgenix) in hemophilia...
Ottawa – January 3, 2024 – Health Canada has authorized Beqvez (fidanacogene elaparvovec), gene therapy for the treatment of hemophilia B. Beqvez is indicated for...
